MedTrace Logo

Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate

NCT06730516 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-12-12

No results posted yet for this study

Summary

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group

Conditions

Interventions

DRUG

Latanoprost (Xalatan)

latanoprost 0.005

DRUG

Brimonidine 0.2 %

Brimonidine0.2

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Yasmine A Deiaeldin, MD · Zagazig University

  • Hani elbialy, MD · Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2024-09-01
Completion
2024-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06730516 on ClinicalTrials.gov